QC
AZN icon

Quadrature Capital’s AstraZeneca AZN Stock Holding History

Quadrature Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
157,534
+150,829
+2,250% +$28.4M 0.26% 87
2026
Q1 		$1.32M Buy
6,705
+3,179
+90% +$613K 0.02% 492
2025
Q4 		$648K Buy
+3,526
New +$618K 0.01% 627

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Quadrature Capital's AZN Position: Q2 2026 in Review

Quadrature Capital increased its AstraZeneca (AZN) stake by 2,250% in Q2 2026, buying an estimated $28.4M and bringing the position to 157,534 shares worth $29.9M. The position accounts for 0.26% of the portfolio, ranked #87.

Quadrature Capital first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Quadrature Capital held 157,534 shares of AstraZeneca worth $29.9M as of Q2 2026.
  • Quadrature Capital bought 150,829 AstraZeneca shares in Q2 2026, an estimated $28.4M.
  • AstraZeneca made up 0.26% of Quadrature Capital's portfolio in Q2 2026, its #87 holding.
  • Quadrature Capital first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.